Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Nosocomial SARS-CoV-2 transmission in multi-bedded hospital cubicles over successive pandemic waves: Lower mortality but wider spread with Omicron despite enhanced infection-prevention measures

Liang En Weea,*, Edwin Philip Conceicaob, May Kyawt Aung b, Myat Oo Aung b, Yong Yangb, Shalvi Arorab, Karrie Kwan-Ki Ko c,d, Indumathi Venkatachalamb

a Department of Infectious Diseases, Singapore General Hospital, Singapore
b Department of Infection Prevention and Epidemiology, Singapore General Hospital, Singapore
c Department of Molecular Pathology, Singapore General Hospital, Singapore
d Department of Microbiology, Singapore General Hospital, Singapore

Received 20 June 2022; received in revised form 14 September 2022; accepted 27 September 2022
Available online 7 October 2022

Abstract Background: Increased transmissibility of severe-acute-respiratory-syndrome-coronavirus-2 (SARS-CoV-2) variants, such as the Omicron-variant, presents an infection-control challenge. We contrasted nosocomial transmission amongst hospitalized inpatients across successive pandemic waves attributed to the Delta- and Omicron variants, over a 9-month period in which enhanced-infection-prevention-measures were constantly maintained. Methods: Enhanced-infection-prevention-measures in-place at a large tertiary hospital included universal N95-usage, routine-rostered-testing (RRT) for all inpatient/healthcare-workers (HCWs), rapid-antigen-testing (RAT) for visitors, and outbreak-investigation coupled with enhanced-surveillance (daily-testing) of exposed patients. The study-period lasted from 21st June 2021 to 21st March 2022. Chi-square test and multivariate-logistic-regression was utilized to identify factors associated with onward transmission and 28d-mortality amongst inpatient cases of hospital-onset COVID-19.

Results: During the Delta-wave, hospital-onset cases formed 2.7% (47/1727) of all COVID-19 cases requiring hospitalisation; in contrast, hospital onset-cases formed a greater proportion (17.7%, 265/1483; odds-ratio, OR = 7.78, 95%CI = 5.65–10.70) during the Omicron-wave, despite universal N95-usage and other enhanced infection-prevention measures that remained unchanged. The odds of 28d-mortality were higher during the Delta-wave compared to the Omicron-wave (27.7%, 13/47, vs. 10.6%, 28/265, adjusted-odds-ratio, aOR = 2.78, 95%
Onward-transmission occurred in 21.2% (66/312) of hospital-onset cases; being on enhanced-surveillance (daily-testing) was independently associated with lower odds of onward-transmission (aOR = 0.18, 95%CI = 0.09–0.38). Costs amounted to $USD7141 per-hospital-onset COVID-19 case.

Conclusion: A surge of hospital-onset COVID-19 cases was encountered during the Omicron-wave, despite continuation of enhanced infection-prevention measures; mortality amongst hospital-onset cases was reduced. The Omicron variant poses an infection-control challenge in contrast to Delta; surveillance is important especially in settings where infrastructural limitations make room-sharing unavoidable, despite the high risk of transmission.

© 2022 Australasian College for Infection Prevention and Control. Published by Elsevier B.V. All rights reserved.

Highlights

- Hospital-onset COVID-19 (HA-COVID-19) cases were monitored over 9 months.
- HA-COVID-19 formed a larger proportion of hospitalized cases during Omicron (vs. Delta).
- Mortality in HA-COVID-19 was reduced during the Omicron wave.
- HA-COVID-19 cases identified via daily testing had lower odds of onwards transmission.

Introduction

While strict infection-prevention measures lower secondary attack-rates of coronavirus-disease-2019 (COVID-19) in healthcare-facilities [1], increased transmissibility of severe-acute-respiratory-syndrome-coronavirus-2(SARS-CoV-2) variants, such as the Omicron-variant, presents infection-control challenges [2]. Various enhanced-infection-prevention measures have been instituted to mitigate nosocomial transmission [2]. In Singapore, emergence of the Delta-variant precipitated comprehensive enhanced-infection-prevention-measures, including universal N95-usage, routine-rostered-testing (RRT) for all inpatients/healthcare-workers (HCWs), rapid-antigen-testing (RAT) for visitors, and outbreak-investigation coupled with enhanced-surveillance (daily-testing) of exposed patients [3–6]. These measures were maintained throughout community-transmission of Delta- and Omicron-variants, allowing nosocomial inpatient transmission to be contrasted across successive waves.

Methodology

Institutional setting, study-period, outcome measures

Our healthcare-campus hosts a 1785-bedded tertiary-hospital and a 545-bed community-hospital. Patients are housed on general-wards containing a mixture of normal-pressure single rooms and 5–6 bedded cohorted-cubicles (beds six-feet apart). Toilet facilities are en-suite in some wards and located outside the cohorted-cubicle/room in others. Each cohorted-cubicle/single room has its own ventilation system, with ≥six air-exchanges/hour, and air is not recirculated between cubicles/rooms. Toilets have their own ventilation system, with all air exhausted to outdoors. Ward areas are air-conditioned, given heat and humidity in tropical Singapore. Air in transplant wards is HEPA-filtered. Almost 13,000 HCWs work on-campus. 89.6% of HCWs and 65.0% of inpatients received 2 doses of mRNA-vaccines by end-June 2021. The study-period lasted from 21st June 2021–21st March 2022. Chi-square test and multivariate-logistic-regression was utilized to identify factors associated with onward transmission and 28d-mortality amongst inpatient cases of hospital-onset COVID-19 using SPSS (version 20.0). Costs arising from hospital-onset COVID-19 cases were also collated.

Definitions

Hospital-onset COVID-19-infection was defined as follows [7].

- Indeterminate-hospital-onset: PCR-positive 3–7d post-admission
- Probable-hospital-onset: PCR-positive 8–14d post-admission
- Definite-hospital-onset: PCR-positive ≥15d post-admission

As inpatient PCR-testing was conducted weekly, prior negative PCR-results up-to 14d prior were utilised to evaluate potential nosocomial-transmission. Incubation-periods were defined as 1–14d prior to positive-PCR. Infectious-period was defined as 2d prior to symptom-onset if symptomatic or 7d prior to positive-PCR if asymptomatic. Significant patient-close-contact was defined as contact within six-feet for ≥15 min [6], during the index-patient’s infectious-period. Onward-transmission was defined as ≥1 hospital-onset COVID-19 cases in the same cohorted-cubicle, or if the index was in a single-room, in the same ward; with overlap during the index-patient’s infectious-period; ending when no cases were diagnosed for 14d. Whenever hospital-onset inpatient cases were identified, exposed inpatient close-contacts who had originally shared the cohorted-cubicle were placed on an enhanced-surveillance regimen (d1/4/7 PCR, daily-RAT post-exposure for 7-days) which
remained unchanged throughout the study-period; however new admissions were still continuously accepted to the cubicle. Patients who subsequently tested positive (RAT/PCR) were transferred immediately to isolation so as not to cohort COVID-19 patients together with patients who tested negative. Onward-transmission was classified as occurring between or beyond adjacent-beds (six-feet-apart). Fully-vaccinated status was defined according to our Ministry of

| Table 1 | Univariate analysis of risk factors for 28-day mortality amongst hospital-onset COVID-19 cases (N = 312). |
|-----------------|----------------------------------------------------|---------------------------------|----------------|
| Covariates (index cases) | 28-day mortality amongst hospital-onset cases (%) | Odds ratio, 95% CI | P-value |
| **Clinical characteristics** | | | |
| Aged<70 years | 12/141 (8.5) | 1.00 | | |
| Aged≥70 years | 29/171 (17.0) | 2.22 (1.07–4.55) | 0.030* |
| Female | 17/122 (13.9) | 1.00 | | |
| Male | 24/190 (12.6) | 0.89 (0.46–1.74) | 0.735 |
| ISARIC score<7 | 3/83 (3.6) | 1.00 | | |
| ISARIC score≥7 | 38/229 (16.6) | 5.31 (1.59–17.69) | 0.002* |
| Not on hemodialysis | 34/257 (13.2) | 1.00 | | |
| On hemodialysis | 7/55 (12.7) | 0.96 (0.40–2.29) | 1.00 |
| Not immunocompromised | 19/112 (17.0) | 1.65 (0.85–3.21) | 0.162 |
| Immunocompromised | 33/118 (28.0) | 1.00 | | |
| Not mobile | 8/194 (4.1) | 0.11 (0.05–0.25) | <0.001* |
| Mobile | 14/66 (21.2) | 1.00 | | |
| Not fully vaccinated | 27/246 (11.0) | 0.46 (0.22–0.93) | 0.039* |
| FULLY VACCINATED | | | |
| Admission characteristics | | | |
| Admitted for ≤7 days prior to diagnosis | 11/124 (8.9) | 1.00 | | |
| Admitted for >7 days prior to diagnosis | 30/186 (16.0) | 1.95 (0.94–4.01) | 0.087 |
| Upper-respiratory-tract-infection | 15/227 (6.6) | 1.00 | | |
| Pneumonia | 26/85 (30.6) | 6.23 (3.10–12.52) | <0.001* |
| Did not require high-dependency/intensive care | 36/298 (12.1) | 1.00 | | |
| Required high-dependency/intensive care | 5/14 (35.7) | 4.04 (1.28–12.74) | 0.025* |
| Did not receive therapeutics | 13/126 (10.3) | 1.00 | | |
| Received therapeutics | 28/186 (15.1) | 1.54 (0.76–3.10) | 0.238 |
| Cycle-threshold value ≥ 20 at onset | 19/151 (12.6) | 1.00 | | |
| Cycle-threshold value < 20 at onset | 22/161 (13.7) | 1.10 (0.57–2.12) | 0.867 |
| Delta variant | 13/47 (27.7) | 1.00 | | |
| Omicron variant | 28/265 (10.6) | 0.31 (0.15–0.65) | 0.004* |

* p-value <0.05.
* Chi-square test.
* ISARIC score: risk stratification score that predicts in-hospital mortality for hospitalised COVID-19 patients, derived from the following variables: age, sex, number of comorbidities, respiratory rate, peripheral oxygen saturation, level of consciousness, urea level, and C reactive protein (score range 0–21 points).

| Table 2 | Multivariate analysis of risk factors for 28-day mortality amongst hospital-onset COVID-19 cases (N = 312). |
|-----------------|----------------------------------------------------|---------------------------------|----------------|
| Covariates (index cases) | Adjusted odds ratio, 95% CI | P-value |
| **Clinical characteristics** | | | |
| ISARIC score≥7 (vs. ISARIC <7) | 3.97 (1.05–14.99) | 0.042* |
| Immunocompromised (vs. not immunocompromised) | 2.00 (0.89–4.53) | 0.093 |
| Mobile (vs. immobile) | 0.11 (0.04–0.28) | <0.001* |
| **Admission characteristics** | | | |
| Pneumonia (vs. upper-respiratory-tract-infection) | 4.63 (2.07–10.33) | <0.001* |
| Required high-dependency/intensive care vs. general ward care | 3.97 (1.03–15.34) | 0.045* |
| Omicron variant (vs. Delta variant) | 0.36 (0.13–0.98) | 0.047* |

* p-value <0.05.
* Multivariate logistic regression.
* ISARIC score: risk stratification score that predicts in-hospital mortality for hospitalised COVID-19 patients, derived from the following variables: age, sex, number of comorbidities, respiratory rate, peripheral oxygen saturation, level of consciousness, urea level, and C reactive protein (score range 0–21 points).
### Table 3  Analysis of risk factors for onward transmission of SARS-CoV-2 from hospital-onset COVID-19 cases (N = 312).

| Covariates (index cases) | Onward transmission amongst hospital-onset cases (N%) | 95% CI | P-value | Transmission beyond immediately-adjacent beds (N%) | 95% CI | P-value |
|--------------------------|-----------------------------------------------------|--------|---------|-----------------------------------------------|--------|---------|
| **Clinical characteristics** | | | | | | |
| Aged < 60 years | 15/75 (20.0) | 1.00 | 0.872 | 11/15 (73.3) | 1.00 | 0.543 |
| Aged 60 years | 51/237 (21.5) | 1.10 (0.56–2.10) | 31/51 (60.8) | 0.56 (0.16–2.02) | 1.00 | 1.00 |
| Female | 22/122 (18.0) | 1.00 | 0.321 | 14/22 (63.6) | 1.00 | 0.00 |
| Male | 44/190 (23.2) | 1.37 (0.77–2.43) | 28/44 (63.6) | 1.00 (0.34–2.90) | 1.00 | 0.374 |
| ISARIC score < 7 | 15/83 (18.1) | 1.00 | 0.530 | 8/15 (53.3) | 1.00 | 0.374 |
| ISARIC score 7 | 51/229 (22.3) | 1.28 (0.69–2.46) | 34/51 (66.7) | 1.75 (0.54–5.64) | 1.00 | 0.139 |
| Not on hemodialysis | 57/257 (22.2) | 1.00 | 0.467 | 34/57 (59.6) | 1.00 | 0.139 |
| On hemodialysis | 9/55 (16.4) | 0.68 (0.32–1.50) | 8/9 (88.9) | 5.41 (0.63–46.23) | 1.00 | 0.799 |
| Not immunocompromised | 40/200 (20.0) | 1.00 | 0.564 | 26/40 (65.0) | 0.86 (0.31–2.40) | 1.00 | 0.131 |
| Immunocompromised | 26/112 (23.2) | 1.21 (0.69–2.12) | 16/26 (61.5) | 2.28 (0.82–6.33) | 1.00 | 0.100 |
| Not mobile | 30/118 (25.4) | 1.00 | 0.156 | 16/30 (53.3) | 1.00 | 0.00 |
| Mobile | 36/194 (18.6) | 0.67 (0.39–1.16) | 26/36 (72.2) | 2.28 (0.82–6.33) | 1.00 | 0.00 |
| Not fully vaccinated | 15/66 (22.7) | 1.00 | 0.736 | 10/15 (65.0) | 1.00 | 0.00 |
| Fully vaccinated | 51/246 (20.7) | 0.89 (0.46–1.71) | 32/51 (62.7) | 0.84 (0.25–2.84) | 1.00 | 0.00 |
| **Ward characteristics** | | | | | | |
| In single room | 1/20 (5.0) | 1.00 | 0.088 | 1/1 (100.0) | 1.00 | 0.00 |
| In cohorted cubicle | 65/292 (22.3) | 5.43 (0.71–41.7) | 41/65 (63.1) | 0.63 (0.52–0.76) | 1.00 | 0.00 |
| Dedicated toilet within | 23/145 (15.9) | 1.00 | 0.037* | 14/23 (60.9) | 1.00 | 0.00 |
| – cohorted cubicle or room | | | | | | |
| Shared toilet (outside cohorted cubicle or room) | 43/167 (25.7) | 1.84 (1.05–3.24) | 28/43 (65.1) | 1.20 (0.42–4.32) | 1.00 | 0.00 |
| General ward | 45/224 (20.1) | 1.00 | 0.538 | 26/45 (57.8) | 2.34 (0.73–7.50) | 1.00 | 0.178 |
| Haematology/oncology/renal ward | 21/88 (23.9) | 1.25 (0.69–2.25) | 16/21 (76.2) | 1.00 | 0.00 |
| General ward | 62/294 (21.1) | 1.00 | 1.00 | 40/62 (64.5) | 1.00 | 0.618 |
| High-dependency/intensive-care-unit | 4/18 (22.2) | 1.07 (0.34–3.36) | 2/4 (50.0) | 0.55 (0.07–4.18) | 1.00 | 0.00 |
| **Admission events** | | | | | | |
| Admitted for ≤ 7 days prior to diagnosis | 26/124 (21.0) | 1.00 | 1.00 | 17/26 (65.4) | 1.00 | 1.00 |
| Admitted for > 7 days prior to diagnosis | 40/188 (21.3) | 1.02 (0.58–1.79) | 25/40 (62.5) | 0.88 (0.32–2.47) | 1.00 | 1.00 |
| Not on enhanced-surveillance (daily testing) prior to diagnosis | 55/183 (30.1) | 1.00 | < 0.001* | 35/55 (63.6) | 1.00 | 1.00 |
| On enhanced-surveillance (daily testing) prior to diagnosis | 11/129 (8.5) | 0.22 (0.11–0.43) | 7/11 (63.6) | 1.00 (0.26–3.84) | 1.00 | 1.00 |
| Did not use common toilet | 27/116 (23.3) | 1.00 | 0.478 | 12/27 (44.4) | 1.00 | 0.010* |
| Used common toilet | 39/196 (19.9) | 0.82 (0.47–1.43) | 30/39 (76.9) | 4.12 (1.44–12.07) | 1.00 | 0.00 |
Health’s guidelines [8]; prior to February 2022, receipt of 2 doses of mRNA vaccines was required to maintain fully-vaccinated status, while after February 2022, receipt of a 3rd booster dose was required to maintain fully-vaccinated status for all adults aged ≥18 years.

### Enhanced infection-prevention measures

Universal-admission-testing for SARS-CoV-2 via PCR and RAT was practiced for all inpatients [4,5], with weekly-PCR/mid-week RAT thereafter for all asymptomatic patients [4]. This testing regimen remained unchanged through the whole study period. Patients who developed new respiratory symptoms/undifferentiated fever were tested at symptom-onset for SARS-CoV-2 via PCR. Inpatients testing positive were managed in designated COVID-19 wards (isolation-areas comprising negative-pressure rooms) separate from patients who tested negative. HCWs in isolation-areas designated for the management of confirmed/suspected COVID-19 cases donned N95-respirators/disposable gloves/gowns/face shields as personal-protective-equipment (PPE), with disposal after each use. All HCWs donned N95 respirators in all clinical-areas as a mandatory minimum. Aerosol-generating-procedures (AGPs) outside of the isolation-ward were performed with HCWs using N95-respirators/disposable gloves/gowns/face shields and in single rooms where feasible. Surgical-mask-usage was mandated for all inpatients and visitors. Two asymptomatic, fully-vaccinated-visitors/inpatient/day were allowed; visitors underwent RAT if visiting ≥30 min [6]. Symptomatic HCWs could access free PCR-testing at Staff Clinic [4].

### Results

Over the study-period, 312 hospital-onset cases were identified, of which the majority (53.8%, 168/312) were probable/definite; the remainder were indeterminate. Up to December 2021, whole-genome-sequencing (WGS) revealed that all hospital-onset-cases were attributable to the Delta-variant (N\textsuperscript{9}Z47) [9]. The first Omicron case was identified in a returned traveler on 24th December 2021. By January 2022, all hospital-onset cases demonstrated S-gene dropout on PCR-testing, indicative of the Omicron-variant. During the Delta-wave, hospital-onset cases formed 2.7% (47/1727) of all COVID-19 cases requiring hospitalisation; in contrast, hospital onset-cases formed a greater proportion (17.7%, 265/1483; odds-ratio, OR\textsuperscript{7}Z0.81, 95%CI\textsuperscript{7}Z0.44\textsuperscript{-1.52}, p\textsuperscript{7}Z0.310). Only 6.4% (3/47) required intensive-care-unit/high-dependency admission during the Delta-wave, while 4.2% (11/265) required intensive-care-unit/high-dependency admission during the Omicron-wave (OR\textsuperscript{7}Z1.54, 95%CI\textsuperscript{7}Z0.45\textsuperscript{-5.31}, p\textsuperscript{7}Z0.701). The majority (76.5%, 36/47) were fully-vaccinated during the
Delta-wave, while 79.2% (210/265) were fully vaccinated during the Omicron-wave (OR = 0.86, 95%CI = 0.41–1.79, p = 0.700). On univariate analysis, older age (age ≥70 years), higher ISARIC-score (≥7), being immobile, partial/unvaccinated status, pneumonia, high-dependency/intensive-care-unit admission, and infection with the Delta-variant were associated with 28-day mortality (Table 1). On multivariate-logistic-regression, higher ISARIC-score (≥7), immobility, pneumonia, and intensive-care-unit/high-dependency admission were all independently associated with 28-day mortality amongst hospital-onset COVID-19 cases (Table 2). The odds of 28-day-mortality were higher during the Delta-wave compared to Omicron (27.7%, 13/47, vs. 10.6%, 28/265, Z 1.75, 95%CI 0.69–2.91). On univariate analysis (Table 3) and multivariate-logistic-regression, being on enhanced-surveillance (d1/4/7 PCR, daily-RAT post-exposure for 7 days) was independently associated with lower odds of onward-transmission (aOR = 0.18, 95%CI = 0.09–0.38), whereas AGPs occurring during the index’s infectious period, prior to positive SARS-CoV-2 testing and subsequent isolation, (aOR = 4.07, 95%CI = 1.88–8.78, p < 0.001), cycle-threshold-value of <20 on PCR-testing (aOR = 1.85, 95% CI = 1.01–3.48), admission to a cubicle/room with a shared toilet (outside cohorted cubicle or room) (aOR = 1.90, 95% CI = 1.01–3.54), and being in a cohorted-cubicle instead of a single-room (aOR = 13.32, 95%CI = 1.63–109.10) were all independently associated with higher odds of onward-transmission. Onward-transmission beyond immediately-adjacent beds occurred in the majority (63.6%, 42/66) and was independently associated with common-toilet usage by the index-case (OR = 4.12, 95%CI = 1.44–12.07) (Table 3). Costs of COVID-19 therapeutics, isolation, COVID-19-related testing and surveillance of exposed inpatients attributable to all hospital-onset inpatient cases (N = 312) amounted to USD$2,228,055, or USD$7141 per-case (Table 4).

**Discussion**

During the Delta-wave, inpatient clusters remained small and sporadic in the setting of comprehensive enhanced infection-prevention measures [10]. However, a surge in nosocomial transmission occurred with the Omicron-variant, despite continuation of all infection-prevention measures. Mortality was reduced during the Omicron-wave, and was comparable to estimates of mortality attributed to hospital-associated influenza [11]. Daily inpatient-testing for COVID-19 cluster-control was associated with reduced onward-transmission in cohorted-cubicles. Additionally, COVID-19 index cases identified in rooms with shared bathroom

| Table 4 | Cost of COVID-19 therapeutics, isolation-ward stay, COVID-19-related laboratory testing and surveillance for exposed inpatients for hospital-onset COVID-19 cases amongst hospitalised inpatients (N = 312). |
|---------|-------------------------------------------------------------------------------------------------|------------------|
| Cost of COVID-19 therapeutics, isolation-ward stay, COVID-19-related laboratory testing and surveillance for exposed inpatients | Number of patient-days (d)/number of tests/number of patients | Total cost (USD$) |
| **COVID-19 therapeutics** | | |
| Antivirals | | |
| Remdesivir | 690d | 362,500 |
| Nirmatrelvir-ritonavir | 5d | 800 |
| Monoclonal antibodies | | |
| Casirivimab-imdevimab | 2d | 2500 |
| Sotrovimab | 21d | 52,000 |
| Tixagevimab-cilgavimab | 2d | 7000 |
| Anti-IL6/JAK1-2 | | |
| Baricitinib | 6d | 75 |
| Tocilizumab | 3d | 2300 |
| **COVID-19 in-hospital isolation** | | |
| Isolation in hospital’s isolation general ward | 3269d | 1,242,700 |
| Isolation in hospital’s isolation intensive-care-unit | 126d | 98,280 |
| **COVID-19 related-testing** | | |
| SARS-CoV-2 PCR | 624 tests | 54,000 |
| SARS-CoV-2 IgG (RBD) | 165 tests | 6000 |
| **Costs of surveillance for exposed inpatients to index hospital-onset COVID-19 cases** | | |
| SARS-CoV-2 PCR on d1/4/7, as well as daily-RAT for 7 days post-exposure | 1045 patients | 399,900 |
| **Total costs** | 2,228,055 |
| **Total cost per patient (N = 312)** | 7141 |
facilities had higher odds of onward transmission; likely due to the possibility of fomite transmission [12] and increased human traffic in shared facilities. Generalisability is limited by our study’s single-site nature; however, continuity of infection-prevention measures allowed contrast between pandemic waves. In conclusion, we highlight the challenge of the Omicron variant when contrasted against Delta and reinforce the importance of reducing onward transmission, especially given infrastructural limitations posed by co-located rooms [13].

Ethics

This study was conducted as part of outbreak-investigation; ethics approval was waived under our institutional-review-board guidelines.

Authorship statement

WLE: Conceptualization; data curation; formal analysis; investigation; methodology; writing- original draft; writing-review and editing. EPC, MKA, AMO, YY, SA: Data curation; formal analysis; investigation; methodology; writing-review and editing. KKK: Investigation; methodology; writing-review and editing. IV: Conceptualization; investigation; methodology; supervision; writing-review and editing.

Conflict of interest

The authors report no conflicts of interest

Funding

This work was not grant-funded. Funding for consumables was provided by the Singapore General Hospital.

Provenance and peer review

Not commissioned; externally peer reviewed.

Acknowledgement

The authors acknowledge the efforts of all colleagues in combating COVID-19.

References

[1] Thompson HA, Mousa A, Dighe A, Fu H, Arnedo-Pena A, Barrett P, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) setting-specific transmission rates: a systematic review and meta-analysis. Clin Infect Dis 2021 Aug 2;73(3):e754–64. https://doi.org/10.1093/cid/ciaa100.

[2] Baker MA, Rhee C, Tucker R, Badwalk A, Coughlin C, Holtzman MA, et al. Rapid control of hospital-based SARS-CoV-2 Omicron clusters through daily testing and universal use of N95 respirators. Clin Infect Dis 2022 Feb 7;cia113. https://doi.org/10.1093/cid/cia113. Epub ahead of print. PMID: 35137035.

[3] Wee LE, Venkatachalam I, Sim XYJ, Tan KB, Wen R, Tham CK, et al. Containment of COVID-19 and reduction in healthcare-associated respiratory viral infections through a multi-tiered infection control strategy. Infect Dis Health 2021 May;26(2):123–31. https://doi.org/10.1016/j.idh.2020.11.004.

[4] Wee LE, Conceicao EP, Aung MK, Oo AM, Yong Y, Venkatachalam I, et al. Rostered routine testing for healthcare workers and universal inpatient screening: the role of expanded hospital surveillance during an outbreak of COVID-19 in the surrounding community. Infect Control Hosp Epidemiol 2021 Aug 6;1–9. https://doi.org/10.1017/ice.2021.366.

[5] Wee LE, Conceicao EP, Sim XYJ, Venkatachalam I, Weng WP, Zakaria ND, et al. Utilisation of rapid antigen assays for detection of SARS-CoV-2 in a low-incidence setting at emergency department triage: does risk-stratification still matter? Infect Control Hosp Epidemiol 2021;1–2. https://doi.org/10.1017/ice.2021.407.

[6] Wee LE, Conceicao EP, Sim JX, Venkatachalam I, Wijaya L. Utilisation of SARS-CoV-2 rapid antigen assays in screening asymptomatic hospital visitors: mitigating the risk in low-incidence settings. Int J Infect Dis 2022 Jan;114:132–4. https://doi.org/10.1016/j.ijid.2021.11.011.

[7] European Centre for Disease Prevention and Control. Surveillance definitions for COVID-19. 2021. Available at: https://www.ecdc.europa.eu/en/covid-19/surveillance/surveillance-defined. Accessed 27/9/2021.

[8] Tan HXS, Pung R, Wang LF, Lye DC, Ong B, Cook AR, et al. Association of homologous and heterologous vaccine boosters with COVID-19 incidence and severity in Singapore. JAMA 2022;327(12):1181–2.

[9] Wee LE, Ko KKK, Conceicao EP, Sim JX, Rahman NA, Tan SYL, et al. Linking sporadic hospital clusters during a community surge of the SARS-CoV-2 delta variant (B.1.617.2): the utility of whole-genome-sequencing. Infect Control Hosp Epidemiol 2022;33(1):45–50. https://doi.org/10.1017/ice.2022.106.

[10] Wee LE, Conceicao EP, Sim JX, Aung MK, Aung MO, Yong Y, et al. Sporadic outbreaks of healthcare-associated COVID-19 infection in a highly-vaccinated inpatient population during a community outbreak of the B.1.617.2 variant: the role of enhanced infection-prevention measures. Am J Infect Control 2022 Apr;50(4):465–8. https://doi.org/10.1016/j.ajic.2022.01.009.

[11] Godoy P, Torner N, Soldevila N, Rius C, Jane M, Martinez A, et al. Working group on the surveillance of severe influenza hospitalized cases in catalonia. Hospital-Acquired influenza infections detected by a surveillance system over six seasons, from 2010/2011 to 2015/2016. BMC Infect Dis 2020 Jan 28;20(1):80. https://doi.org/10.1186/s12879-020-04792-7.

[12] Al Mayahi ZK, Al Kindi N, Al Shaqsi N, Al Hattali N, Al Hattali A, Salim K, et al. Non-respiratory droplet transmission of COVID-19 in the isolation ward of a secondary hospital in Oman: a return to isolation basics. Infect Dis Clin Pract 2021 Nov;29(6):e371–5. https://doi.org/10.1097/IPC.0000000000001022.

[13] Karan A, Klompas M, Tucker R, Baker M, Vaidya V, Rhee C. The risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission from patients with undiagnosed coronavirus disease 2019 (COVID-19) to roommates in a large academic medical center. Clin Infect Dis 2022 Mar 23;74(6):1097–100. https://doi.org/10.1093/cid/ciab564.